Connor, Clark & Lunn Investment Management (CC&L)’s Amneal Pharmaceuticals AMRX Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $4.87M | Buy |
602,468
+74,783
| +14% | +$605K | 0.02% | 581 |
|
|
2025
Q1 | $4.42M | Sell |
527,685
-27,970
| -5% | -$234K | 0.02% | 531 |
|
|
2024
Q4 | $4.4M | Buy |
555,655
+6,680
| +1% | +$52.9K | 0.02% | 515 |
|
|
2024
Q3 | $4.57M | Sell |
548,975
-9,138
| -2% | -$76K | 0.02% | 453 |
|
|
2024
Q2 | $3.54M | Buy |
558,113
+24,679
| +5% | +$157K | 0.01% | 512 |
|
|
2024
Q1 | $3.23M | Buy |
533,434
+56,528
| +12% | +$343K | 0.01% | 535 |
|
|
2023
Q4 | $2.89M | Sell |
476,906
-15,398
| -3% | -$93.5K | 0.01% | 577 |
|
|
2023
Q3 | $2.08M | Buy |
492,304
+107,090
| +28% | +$452K | 0.01% | 615 |
|
|
2023
Q2 | $1.19M | Buy |
385,214
+54,717
| +17% | +$170K | 0.01% | 745 |
|
|
2023
Q1 | $459K | Buy |
330,497
+96,380
| +41% | +$134K | ﹤0.01% | 911 |
|
|
2022
Q4 | $466K | Buy |
234,117
+80,427
| +52% | +$160K | ﹤0.01% | 877 |
|
|
2022
Q3 | $310K | Buy |
+153,690
| New | +$310K | ﹤0.01% | 915 |
|
|
2020
Q4 | – | Sell |
-18,014
| Closed | -$70K | – | 888 |
|
|
2020
Q3 | $70K | Sell |
18,014
-281,053
| -94% | -$1.09M | ﹤0.01% | 886 |
|
|
2020
Q2 | $1.42M | Buy |
299,067
+116,776
| +64% | +$556K | 0.01% | 530 |
|
|
2020
Q1 | $634K | Buy |
+182,291
| New | +$634K | 0.01% | 648 |
|